Dr. Hansen should know at least one aspect of leronlimab and it's effect on cancer. He is helping uncover the structure of PI3K. Leronlimab downregulates PI3K.

Quote:

---

Biopharma companies are trying to develop drugs that target and inactivate these enzymes, known as phosphoinositide 3-kinase, or PI3K for short, because of their role in causing cancers in humans. But to do that, scientists need a detailed blueprint of the enzyme architecture, and UO biochemistry professor Scott Hansen is part of a group uncovering that diagram.
https://around.uoregon.edu/content/chemists-d...ved-cancer

---